Andreas Muehler
Chief Tech/Sci/R&D Officer chez IMMUNIC, INC.
Fortune : 403 011 $ au 31/03/2024
Profil
Andreas Muehler is the founder of Immunic AG, which was founded in 2016, where he holds the title of Chief Medical Officer.
He is currently the Chief Medical Officer at Immunic, Inc. since 2016.
Dr. Muehler's former positions include President & Chief Executive Officer at MicroMRI, Inc. from 2008 to 2010, Chief Executive Officer & VP-Corporate Development at Cellectar, Inc., Managing Director at STRIVE Healthcare GmbH, Chief Medical Officer at Vital Therapies, Inc., and President at CAD Sciences LLC.
Dr. Muehler's education includes an MBA from Duke University and a doctorate from Humboldt-Universität zu Berlin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMUNIC, INC.
0,34% | 04/03/2024 | 305 311 ( 0,34% ) | 403 011 $ | 31/03/2024 |
Postes actifs de Andreas Muehler
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNIC, INC. | Chief Tech/Sci/R&D Officer | 01/08/2016 |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Founder | 01/04/2016 |
Anciens postes connus de Andreas Muehler
| Sociétés | Poste | Fin |
|---|---|---|
CAD Sciences LLC
 CAD Sciences LLC Packaged SoftwareTechnology Services CAD Sciences LLC develops computer-assisted visualization of contrast enhancement in MR imaging of cancer. The company was founded by Jordan R. Metzger on March 1, 2002 and is headquartered in White Plains, NY. | President | 01/01/2006 |
Cellectar, Inc.
 Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Chief Executive Officer | - |
STRIVE Healthcare GmbH
 STRIVE Healthcare GmbH Financial ConglomeratesFinance Part of S-VG Sommer Vermögensverwaltung GmbH & Co. KG, STRIVE Healthcare GmbH is a German company that invests in the healthcare sector. The private company is based in Munich, Germany. The CEOs of the company are Angela Liedler, Eric Frieman. STRIVE Healthcare was acquired by Palladius AG from S-VG Sommer Vermögensverwaltung GmbH & Co. KG on November 07, 2008. | Chief Executive Officer | - |
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
MicroMRI, Inc.
 MicroMRI, Inc. Electronic Equipment/InstrumentsElectronic Technology MicroMRI, Inc. develops medical devices. It focuses on developing and commercializing novel and innovative products that perform high resolution Magnetic Resonance Imaging (MRI) of bone micro-architecture with subsequent detailed visualization of bone structural elements. The company was founded by Onne Ganel and Bryon Gomberg on September 19, 2003 and is headquartered in Philadelphia, PA. | Chief Executive Officer | 27/04/2010 |
Formation de Andreas Muehler
| Duke University | Masters Business Admin |
| Humboldt-Universität zu Berlin | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMUNIC, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
MicroMRI, Inc.
MicroMRI, Inc. Electronic Equipment/InstrumentsElectronic Technology MicroMRI, Inc. develops medical devices. It focuses on developing and commercializing novel and innovative products that perform high resolution Magnetic Resonance Imaging (MRI) of bone micro-architecture with subsequent detailed visualization of bone structural elements. The company was founded by Onne Ganel and Bryon Gomberg on September 19, 2003 and is headquartered in Philadelphia, PA. | Electronic Technology |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Health Technology |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Commercial Services |
CAD Sciences LLC
CAD Sciences LLC Packaged SoftwareTechnology Services CAD Sciences LLC develops computer-assisted visualization of contrast enhancement in MR imaging of cancer. The company was founded by Jordan R. Metzger on March 1, 2002 and is headquartered in White Plains, NY. | Technology Services |
STRIVE Healthcare GmbH
STRIVE Healthcare GmbH Financial ConglomeratesFinance Part of S-VG Sommer Vermögensverwaltung GmbH & Co. KG, STRIVE Healthcare GmbH is a German company that invests in the healthcare sector. The private company is based in Munich, Germany. The CEOs of the company are Angela Liedler, Eric Frieman. STRIVE Healthcare was acquired by Palladius AG from S-VG Sommer Vermögensverwaltung GmbH & Co. KG on November 07, 2008. | Finance |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Health Technology |
